8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: November 06, 2006 (Date of earliest event reported)
Aradigm (Exact name of registrant as specified in its charter)
CA (State or other jurisdiction of incorporation)	0-28402 (Commission File Number)	94-3133088 (IRS Employer Identification Number)
3929 Point Eden Way (Address of principal executive offices)		94545 (Zip Code)
5102659000 (Registrant's telephone number, including area code)
Not Applicable (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On November 6, 2006, the Company issued a press release announcing the election of John M. Siebert, Ph.D. to the Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:
            None
(b) Pro forma financial information:
            None
(c) Shell company transactions:
            None
(d) Exhibits
            99.1       Press Release entitled "ARADIGM NAMES JOHN SIEBERT TO THE BOARD OF DIRECTORS" issued by the Company on November 6, 2006

SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 06, 2006
ARADIGM By:  /s/ Thomas C. Chesterman                    
     Thomas C. Chesterman
     SVP and CFO

Exhibit Index
Exhibit No.	Description
99.1	Press Release entitled "ARADIGM NAMES JOHN SIEBERT TO THE BOARD OF DIRECTORS" issued by the Company on November 6, 2006

EX-99 2 aradigm8k180780.htm ARADIGM PRESS RELEASE Aradigm Names John Siebert to the Board of Directors

HAYWARD, CA -- 11/06/2006 -- The Board of Directors of Aradigm Corporation (NASDAQ: ARDM) today announced the appointment of John M. Siebert, Ph.D. to the Board of Directors. Dr. Siebert is currently the Chairman and CEO of CyDex, a privately-held company that has been successfully out-licensing its substituted cyclodextrin technology for use in drug development and formulation to a number of major pharmaceutical companies. CyDex also uses that technology to develop proprietary products which are out-licensed or may be brought to market by CyDex in the future.

Dr. Siebert joined CyDex as Chief Executive Officer in 2003 and has focused the company on developing pharmaceutical products using CyDex's innovative drug delivery platform technology. The business model is similar to that used by Dr. Siebert at CIMA Labs, Inc. prior to joining CyDex. Dr. Siebert was President and Chief Executive Officer of CIMA Labs, Inc., leading that company's transition from a small drug delivery firm to a successful and profitable specialty pharmaceutical company. Prior to joining CIMA, Dr. Siebert had served in scientific, quality assurance and product development roles with G. D. Searle, E.R.Squibb, Bayer and Procter & Gamble. Dr. Siebert also held various senior executive positions at Dey Laboratories, a company that develops, manufactures and markets innovative airway and allergy medications. He has over 36 years of pharmaceutical industry experience. He holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University, and a Ph.D. in Organic Chemistry from the University of Missouri.

Dr Siebert said: "I am pleased to join Aradigm's Board to assist the company in its important transformation from the provider of innovative pulmonary delivery technologies to a respiratory specialty pharmaceutical company focusing on development of better products for patients with severe lung diseases."

Virgil Thompson, Aradigm's Chairman, said, "John brings a wealth of experience in drug development to Aradigm, and should prove quite helpful as Aradigm executes its vision and strategy of becoming a specialty pharmaceutical company."

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm.

Additional information about Aradigm can be found at www.aradigm.com.

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including preclinical and clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm Corporation.

Contact:
Investor Relations
Aradigm Corporation
(510) 265-9370

-----END PRIVACY-ENHANCED MESSAGE-----

EX-99

Aradigm Names John Siebert to the Board of Directors

HAYWARD, CA -- 11/06/2006 -- The Board of Directors of Aradigm Corporation (NASDAQ: ARDM) today announced the appointment of John M. Siebert, Ph.D. to the Board of Directors. Dr. Siebert is currently the Chairman and CEO of CyDex, a privately-held company that has been successfully out-licensing its substituted cyclodextrin technology for use in drug development and formulation to a number of major pharmaceutical companies. CyDex also uses that technology to develop proprietary products which are out-licensed or may be brought to market by CyDex in the future.

Dr. Siebert joined CyDex as Chief Executive Officer in 2003 and has focused the company on developing pharmaceutical products using CyDex's innovative drug delivery platform technology. The business model is similar to that used by Dr. Siebert at CIMA Labs, Inc. prior to joining CyDex. Dr. Siebert was President and Chief Executive Officer of CIMA Labs, Inc., leading that company's transition from a small drug delivery firm to a successful and profitable specialty pharmaceutical company. Prior to joining CIMA, Dr. Siebert had served in scientific, quality assurance and product development roles with G. D. Searle, E.R.Squibb, Bayer and Procter & Gamble. Dr. Siebert also held various senior executive positions at Dey Laboratories, a company that develops, manufactures and markets innovative airway and allergy medications. He has over 36 years of pharmaceutical industry experience. He holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University, and a Ph.D. in Organic Chemistry from the University of Missouri.

Dr Siebert said: "I am pleased to join Aradigm's Board to assist the company in its important transformation from the provider of innovative pulmonary delivery technologies to a respiratory specialty pharmaceutical company focusing on development of better products for patients with severe lung diseases."

Virgil Thompson, Aradigm's Chairman, said, "John brings a wealth of experience in drug development to Aradigm, and should prove quite helpful as Aradigm executes its vision and strategy of becoming a specialty pharmaceutical company."

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm.

Additional information about Aradigm can be found at www.aradigm.com.

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including preclinical and clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm Corporation.

Contact:
Investor Relations
Aradigm Corporation
(510) 265-9370